The wearable cardioverter-defibrillator is not needed for most high-risk patients

Key Findings▪Since FDA approval nearly 20 years ago, only a single wearable cardioverter-defibrillator (WCD) is commercially available in the world.▪The use of the WCD seems justified “as a bridge” in certain niche conditions such as infection or pre cardiac transplant; randomized clinical trials in these patient populations are not practical.▪The single randomized clinical trial ever performed with this technology failed to meet its primary...